Gennex Laboratories Share Price

LG Electronics India receives Sebi approval for Rs 15,000 crore IPO

Higher mineral tax likely to pose a challenge to cement sector recovery

IndusInd Bank most-sold stock by mutual funds in February, shows data

Private equity's next leap hinges on local fund needs and buyouts

Secondary deals to drive PE exits as IPO window narrows: Ranu Vohra

Pursuant to SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31 2024 and BSE Notice No. 20250102-4 dated January 02 2025 and your email dated March 03 2025 please find herewith the report on Integrated Filing (Financial) for the Quarter and Nine months ended December 31. 2024.We request you to take the above information on record and acknowledge receipt of the same.

Pursuant to Regulation 47 of SEBI (LODR) Regulations 2015 please find enclosed herewith Newspaper Publication on Unaudited (Standalone and Consolidated) Financial Results for the Quarter and Nine months ended December 31 2024 announced by the Board of Directors in its Meeting held on February 14 2025. financial Results had been published in both Financial Express (English) and Saksham (Telugu - Local) on Sunday Friday 16 2025.We request you to take the above information on record and acknowledge receipt of the same.

In just concluded Meeting of Board of Directors the Board considered and approved the following items:1. Unaudited (Standalone and Consolidated) Financial Statements for the Quarter and Nine months ended December 31 2024.2. Limited Review Reports from the Statutory Auditors on Unaudited (Standalone and Consolidated) Financial Statements for the Quarter and Nine months ended December 31 2024.3. Resignation of Mr. Mohammed Khaleequr Rahman Non-Executive Non-Independent Director of the Company.4. Other Business items.We hereby submit that the Board Meeting had commenced at 4.00 PM and concluded at 6.15 PM.The intimation is also being uploaded on the Company website: www.gennexlab.comWe request you to take the above information on record and acknowledge receipt of the same.

In just concluded Meeting of Board of Directors the Board considered and approved the following items1. Unaudited (Standalone and Consolidated) Financial Statements for the Quarter and Nine months ended December 31 20242. Limited Review Report from the Statutory Auditor on Unaudited (Standalone and Consolidated) Financial Statements for the Quarter and Nine months ended December 31 2024.3. Resignation of Mr. Mohammed Khaleequr Rahman Non-Excutive and Non-Independent Director of the Company4. Other Business itemsWe hereby submit that the Board Meeting commenced at 4.00 PM and concluded at 6.15 PM.The intimation is also being uploaded on the Company Website: www.gennexlab.com.We request you to take the above information on record and acknowledge receipt of the same.

Pursuant to Regulation 32 of SEBI (LODR) Regulations 2015 we hereby confirm that there is no deviation or variation in the use of the proceeds during the quarter ended December 31 2024 from the objects stated in the letter of offer for the funds raised by the Company. A Statement of Deviation stating that there is no deviation or variation in the utilization of proceeds duly reviewed by the Audit Committee is attached.We request you take the above information on record and acknowledge receipt of the same.